Galmed Pharmaceuticals Ltd. (GLMD) Social Stream

Featured Post From StockTwits About GLMD

$GLMD New Press Release:

MHRA Agrees with Galmed's Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the Medicines and Healthcare products Regulatory Agency (MHRA), the pharmaceuticals regulator in the UK, agreed with Galmed's plan to proceed with its proposed clinical studies with Aramchol meglumine in lieu of Aramchol free acid without the need to repeat nonclinical and clinical studies other than planned limited (...)

https://wchr.one/114319